These data suggest that P2Y6 may be a potential pharmacologic target to restrict both feeding and systemic insulin resistance in obesity and that P2Y6 receptor antagonism may have efficacy in reversing central programming effects in offspring induced as a consequence of maternal obesity. The gene discussed is P2RY6; the disease is obesity disorder.